ConductScience.org, home

Comparison · NCT01369212-e8610160

Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With HBeAg Loss at Week 240

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With HBeAg Loss at Week 240. Trial comparisons, record NCT01369212-e8610160. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01369212-e8610160

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.3880.2640.528wilson
Risk in group 20.6220.4760.749wilson
Risk difference, group 1 minus group 2-0.234-0.411-0.0324newcombe hybrid score
Risk ratio, group 1 over group 20.6230.410.948log
Odds ratio, group 1 over group 20.3850.1670.884log
Number needed to treat, for one fewer participant with the outcome on Tenofovir than on Peginterferon-alfa 2a and Tenofovir4.262.4330.9from the risk difference interval

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1TenofovirTenofovir 192 weeks~Tenofovir: 300 mg daily for 192 weeks (4 years)1949OG000
Group 2Peginterferon-alfa 2a and Tenofovir
A combination of peginterferon-alfa 2a plus tenofovir for 24 weeks and then tenofovir only for 168 weeks~Peginterferon-alfa 2a and tenofovir: A combination of peginterferon-alfa 2a 180 µg weekly plus tenofovir 300 mg daily for 24 weeks and then only tenofovir 300 mg daily for 168 weeks (3.5 years).
2845OG001

Outcome

Type
SECONDARY
Title
Number of Participants With HBeAg Loss at Week 240
Description
Number of participants who became HBeAg negative at week 240 among HBeAg positive participants at baseline
Time frame
week 240
Population
Participants who were HBeAg positive at baseline and who had data for HBeAg at week 240 visit

Source ClinicalTrials.gov

Trial

Title
Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B
NCT number
NCT01369212
Phases
PHASE3
Conditions
Hepatitis B
Interventions
Tenofovir, Peginterferon-alfa 2a and tenofovir
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Results first posted
2022-10-12

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01369212-e8610160